Credit: Shutterstock. Asundexian is an investigational oral Factor XIa inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to asundexian for the prevention of stroke ...

Avicenna.AI SAS received clearance from the U.S. FDA for two of its artificial intelligence (AI)-based solutions, Cina-Ipe and Cina-Aspects, which provide for the detection of pulmonary embolism (PE) ...

Please provide your email address to receive an email when new articles are posted on . Rivaroxaban did not lower the composite outcome of stroke, systemic embolism and new covert embolism stroke vs.

During the AHA Scientific Sessions 2025, a session was presented that focused on dilemmas related to antithrombotic therapy following catheter ablation in patients with AF. A session presented at the ...